Refractory Lymphoma Clinical Trials

10 recruiting

Frequently Asked Questions

Common questions about Refractory Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 119 of 19 trials

Recruiting
Phase 2

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic LeukemiaRecurrent LymphomaRecurrent Diffuse Large B-Cell Lymphoma+5 more
Mayo Clinic80 enrolled4 locationsNCT03418038
Recruiting
Phase 1

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

Non-Hodgkin LymphomaRefractory LymphomaChimeric Antigen Receptor T-cell
The First Affiliated Hospital of Xiamen University45 enrolled1 locationNCT06875063
Recruiting
Phase 1

Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma

Relapsed or Refractory Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd18 enrolled1 locationNCT07453446
Recruiting
Phase 1Phase 2

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Lymphoma+7 more
Children's Oncology Group63 enrolled34 locationsNCT04870944
Recruiting
Phase 2

Epco, Zanu, Ritux for R/R FL or MZL

Non-Hodgkin LymphomaLymphomaFollicular Lymphoma+3 more
Reid Merryman, MD45 enrolled3 locationsNCT06563596
Recruiting
Phase 1Phase 2

Avo In R/R And Previously Untreated MCL

Mantle Cell LymphomaRefractory Lymphoma
Austin I Kim72 enrolled3 locationsNCT04855695
Recruiting
Phase 1Phase 2

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Locally AdvancedUnresectableMetastatic Cancers+1 more
Recursion Pharmaceuticals Inc.85 enrolled6 locationsNCT06678659
Recruiting
Phase 1

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Refractory LymphomaRelapsed CLLRefractory CLL
Paolo Caimi, MD18 enrolled1 locationNCT06916767
Recruiting
Phase 1Phase 2

Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

Relapsed/refractory Lymphoma
Hangzhou Hanx Biopharmaceuticals, Ltd.99 enrolled1 locationNCT05189093
Recruiting
Phase 1Phase 2

A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL

Natural Killer/T-cell LymphomaRelapsed or Refractory Lymphoma Including ENKL
Fudan University68 enrolled1 locationNCT06966154
Recruiting
Phase 2

Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure

Diffuse Large B Cell LymphomaRelapsed or Refractory LymphomaHigh-grade B-cell Lymphoma (HGBCL)+1 more
Istituto Clinico Humanitas50 enrolled7 locationsNCT06918912
Recruiting
Phase 1

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

Advanced Solid TumorRelapsed or Refractory Lymphomas
Lantern Pharma Inc.110 enrolled4 locationsNCT06132503
Recruiting
Phase 1

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

Advanced/Metastatic Solid TumorsRelapse/Refractory Lymphoma
EpimAb Biotherapeutics (Suzhou)Co., Ltd.150 enrolled10 locationsNCT05607498
Recruiting
Phase 2

Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma

LymphomaFollicular LymphomaRefractory Lymphoma
The First Affiliated Hospital of Xiamen University30 enrolled1 locationNCT06826118
Recruiting
Early Phase 1

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

Relapsed/refractory LymphomaRelapsed/Refractory Leukemia
Affiliated Hospital of Nantong University9 enrolled1 locationNCT06756321
Recruiting

Solving Riddles Through Sequencing

LeukemiaHematologic MalignancyUnknown Primary Tumors+3 more
Munich Leukemia Laboratory100 enrolled1 locationNCT05046444
Recruiting
Phase 1

A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor

Advanced Solid TumorsRefractory LymphomaRelapsed Hematologic Malignancy
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.111 enrolled8 locationsNCT06615193
Recruiting
Early Phase 1

Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma

Relapsed/refractory Lymphoma
Shanghai First Song Biotechnology Co., LTD9 enrolled1 locationNCT06532643
Recruiting

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

Advanced LymphomaRefractory Acute Myeloid LeukemiaRefractory Lymphoma+2 more
Medical University of Vienna150 enrolled1 locationNCT04470947